Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

45-percent cutoff in solid fat, added sugar intake identifies low-quality diets

04 Oct 2020

Use of the 45-percent cutoff point for the contribution of solid fat and added sugars (SoFAS) foods to total energy intake is helpful in identifying high-risk eating profile in a Brazilian population, according to a study.

“In recent decades, changes in the diet of Brazilians have been characterized by increased consumption of high energy-dense foods, rich in fat and sugar,” the authors said.

To assess diet quality based on the intake of foods with high content of SoFAS, the first Brazilian National Dietary Survey (2008–2009) was conducted. This nationwide representative cross-sectional study collected food records from 34,003 individuals aged ≥10 years.

The authors used a receiver-operating characteristic curve to determine the limit that would identify diets with high SoFAS content.

The 45-percent limit of total dietary energy provided by SoFAS was adopted to classify diets with excessive content. The SoFAS provided 53 percent of daily energy intake to adolescents, 49 percent to adults, and 48 percent to the elderly. Majority of the adolescents (64.7 percent), adults (59.1 percent), and the elderly (57.8 percent) had a high intake of SoFAS.

Higher income was associated with the increased contribution of SoFAS to daily energy intake in all age groups. In addition, individuals with high consumption of SoFAS had higher intakes of sugar-sweetened beverages, cookies and cakes, processed meats, chips, candy and chocolate, and sandwiches and snacks when compared with those who had moderate intake of SoFAS (<45 percent of daily energy).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.